Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heberprot-P in Diabetic Foot Ulcer
NCT02554851Phase 3Unknown
- Sponsor
- Immunobiological Technology Institute
- Start
- Jan 2017
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in diabetic foot ulcer (DFU) comparing Placebo with Heberprot-P (2 arms). Primary endpoint: Proportion of participants with 100% healing up to 9 months. Status: unknown.
02
Drugs
epidermal growth factor
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02554851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02554851.